GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Forward PE Ratio

Heidelberg Pharma AG (XTER:HPHA) Forward PE Ratio : 0.00 (As of Jun. 21, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Forward PE Ratio?

Heidelberg Pharma AG's Forward PE Ratio for today is 0.00.

Heidelberg Pharma AG's PE Ratio without NRI for today is 0.00.

Heidelberg Pharma AG's PE Ratio for today is 0.00.


Heidelberg Pharma AG Forward PE Ratio Historical Data

The historical data trend for Heidelberg Pharma AG's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Forward PE Ratio Chart

Heidelberg Pharma AG Annual Data
Trend 2019-12 2020-01
Forward PE Ratio
106.38 131.58

Heidelberg Pharma AG Quarterly Data
2019-12
Forward PE Ratio 106.38

Competitive Comparison of Heidelberg Pharma AG's Forward PE Ratio

For the Biotechnology subindustry, Heidelberg Pharma AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Forward PE Ratio falls into.



Heidelberg Pharma AG Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Heidelberg Pharma AG  (XTER:HPHA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Heidelberg Pharma AG Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines